Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record.

The pharmacology of cilostazol

Schrör, Karsten · 2002 · Diabetes, Obesity and Metabolism

Abstract

Cilostazol (6‐[4‐(1‐cyclohexyl‐ 1H ‐tetrazol‐5‐yl)butoxy]‐3,4‐dihydro‐2(1 H )‐quinolinone; OPC‐13013) is a 2‐oxo‐quinoline derivative with antithrombotic, vasodilator, antimitogenic and cardiotonic properties. The compound is a potent inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system (IC 50 : 0.2 µ m ). In addition, there is inhibition of adenosine uptake, eventually resulting in changes in cAMP levels, dependent on the type of adenosine receptors (A 1 or A 2 ). Cilostazol inhibits platelet aggregation and has considerable antithrombotic effects in vivo . The compound relaxes vascular smooth muscle and inhibits mitogenesis and migration of vascular smooth muscle cells. In the heart, cilostazol causes positive inotropic and chronotropic effects. Most, if not all, of these actions are cAMP‐mediated, including the modification of cAMP‐controlled gene expression. Cilostazol decreases levels of serum triglycerides and causes some increase in HDL‐cholesterol levels. The compound has a number of additional effects which might contribute to its overall clinical efficacy. Cilostazol undergoes intensive and finally complete hepatic metabolism via the cytochrome P450 systems. This might result in some drug interaction, i.e. with erythromycin and omeprazole. The half‐life is approximately 10 h, resulting in about 2‐fold accumulation of the drug during repeated administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2002.0040s2s14.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 213

Metadata

Authors
Schrör, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2002-03
Volume
4
Issue
s2
Pages
S14-9
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2029618578
Cited by
213
References
0
FWCI
1.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacology of cilostazol. https://app.cochat.ai/papers/10.1046/j.1463-1326.2002.0040s2s14.x
The paper
Schrör, K. (2002). The pharmacology of cilostazol. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2002.0040s2s14.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.